Bromocriptine as initial therapy in elderly parkinsonian patients. The Bromocriptine Multicentre Trial Group.

The problems of long-term levodopa treatment are well established, and a number of studies describe the use of bromocriptine as a first-line agent in patients under 65 years. This multicentre double-blind study compared the efficacy of low and very low dose bromocriptine in 64 elderly subjects with newly diagnosed Parkinson's disease. Both regimens led to clinical improvement, but there was a high drop-out rate and a high mortality. These difficulties, together with a low recruitment rate, resulted in problems of statistical analysis. There was no significant advantage in using the higher of the two dosage regimens, and we would recommend a maintenance dosage range of 5 mg-15 mg bromocriptine daily. On the basis of this study, however, bromocriptine seems unlikely to replace levodopa as the first-line treatment for Parkinson's disease.
JournalAge and ageing (Age Ageing) Vol. 19 Issue 1 Pg. 62-7 (Jan 1990) ISSN: 0002-0729 [Print] ENGLAND
PMID2180259 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Bromocriptine
  • Aged
  • Aged, 80 and over
  • Bromocriptine (administration & dosage, therapeutic use)
  • Double-Blind Method
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Parkinson Disease (diagnosis, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: